title: Human soluble p66 and p51 tumor-associated antigens promote the suppression of rat mammary tumors in comparison to commercial human albumin.
abstract: This study examined whether the soluble 66- and 51 kDa tumor-associated antigens (sTAA), isolated from the serum of breast cancer patients, possess specific suppressive effects on chemically-induced rat mammary tumorigenesis in comparison to commercial human albumin. Dimethylbenzanthracene (DMBA, 10 mg/rat, 2 administrations) was used to induce mammary tumors in 8-week-old Sprague Dawley rats. After the appearance of many large tumors, preparations of sTAA (50-60 micro g/rat in 0.5 ml sterile PBS) or commercial human albumin (HA, in the same doses as sTAA) were administered weekly, for 10-14 more weeks. The following groups of mammary tumor-bearing rats were studied: i) control non-treated rats, ii) rats treated with HA, iii) rats treated with sTAA. The experiment was terminated when tumors in 70% of the rats became ulcerous. The treatment with sTAA significantly decreased, compared to controls, the yield and total area of the tumors. In rats treated with sTAA, the appearance of new tumors stopped at week 5 as compared to week 7 in rats treated with HA and week 10 in control rats. In rats treated with sTAA, the time of appearance of ulcerous tumors increased to 8 weeks, as compared to 6 weeks in controls and in rats treated with HA. Duration of the experiment increased from 11 weeks in controls to 12 weeks in rats treated with HA and to 14 weeks in rats treated with sTAA. We conclude that sTAA have tumor-suppressive properties, which are well-defined if the treatment is begun on small tumors.
authors.affiliation: Laboratory of Experimental Oncology, Koret School of Veterinary Medicine, Faculty of Agricultural, Food and Environmental Quality Sciences, The Hebrew University of Jerusalem, PO Box 12, Rehovot 76100, Israel.
authors.forename: George
authors.initials: G
authors.lastname: Kossoy
authors.forename: Ilana
authors.initials: I
authors.lastname: Avinoach
authors.forename: Itshak
authors.initials: I
authors.lastname: Zusman
authors.forename: David P
authors.initials: DP
authors.lastname: Scheider
authors.forename: Herzl
authors.initials: H
authors.lastname: Ben-Hur
authors.forename: Asher
authors.initials: A
authors.lastname: Elhayany
mesh_terms: D015127:9,10-Dimethyl-1,2-benzanthracene; D000818:Animals; D016588:Anticarcinogenic Agents / Q000627:therapeutic use; D000951:Antigens, Neoplasm / Q000302:isolation & purification* / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D008325:Mammary Neoplasms, Experimental / Q000139:chemically induced / Q000473:pathology* / Q000517:prevention & control*; D008970:Molecular Weight; D051381:Rats; D012709:Serum Albumin / Q000627:therapeutic use*
chemical_list: D016588:Anticarcinogenic Agents; D000951:Antigens, Neoplasm; D012709:Serum Albumin; D015127:9,10-Dimethyl-1,2-benzanthracene